ROCHESTER, N.Y., June 19, 2014 /PRNewswire/
-- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of
clinical trial imaging solutions, today announced that shareholders
have voted for and ratified all four proposals contained in the
company's 2014 proxy statement. The outcome of yesterday's
vote at the Annual Meeting of Shareholders is as follows:
- Re-elected to the Board of Directors to serve until the 2015
Annual Meeting are Robert G.
Klimasewski, Eric T.
Converse, Bruce L. Lev,
Charles E. Phelps and Terence A. Walts. David Rubin, who serves as the director designee
of the holders of the company's Series C-1 preferred stock, has
also been re-elected.
- Marcum LLP was named the company's independent registered
public accounting firm for the fiscal year ending December 31, 2014.
- Approval of an amendment to the company's Certificate of
Incorporation to decrease the authorized common stock and
authorized undesignated preferred stock.
- Approval of compensation for certain executive officers.
Five members of VirtualScopics' senior management team made
presentations reviewing the company's business and future
outlook. The Annual Meeting of Shareholders was webcast live
and a replay of the meeting and accompanying slide presentations
can be found on the company's website, www.virtualscopics.com,
under "investors" and "webcasts" or at
http://www.investorcalendar.com/IC?CEPage.asp?ID=172786.
About VirtualScopics, Inc.
Virtual Scopics, Inc.
(NASDAQ:VSCP) is a leading provider of clinical trial imaging
solutions to accelerate drug and medical device development.
For risk-averse, time-constrained Clinical Trial Study Teams,
Medical Directors and Imaging Scientists who require quality
imaging data delivered on-time, within budget and on a consistent
basis, VirtualScopics' clinical trial imaging solutions are an
inspired true-exception to commonly accepted services provided by
other clinical trial imaging providers. Because of the
scientific and operational flexibility and responsiveness they can
offer, VirtualScopics' clinical trial imaging solutions deliver
special performance advantages compared to other image service
providers that offer common, every day clinical trial imaging
services. For more information about VirtualScopics, Inc.
please visit www.virtualscopics.com.
For More Information, Contact:
Donna N. Stein, APR, Fellow PRSA
Managing Partner, Donna Stein &
Partners
Phone: 315-361-4672
Email: dstein1@twcny.rr.com
SOURCE VirtualScopics, Inc.